Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0225 • ACR Convergence 2023
Breakthrough SARS-Cov-2 Infection and Disease Flares in Patients with Rheumatoid Arthritis: Result from COVAD E-Survey Study
Yi-Ming Chen¹, Jun-Pen Chen², Chi-Wei Tseng², CARLOS ENRIQUE TORO GUTIERREZ³, Elena Nikiphorou⁴, Ai Lyn Tan⁵, Arvind Nune⁶, Esha Kadam⁷, Masataka Kuwana⁸, Jessica Day⁹, Sreoshy Saha¹⁰, Tsvetelina Velikova¹¹, James Lilleker¹², CARLO VINICIO CABALLERO¹³, Parikshit Sen¹⁴, Hector Chinoy¹⁵, Rohit Aggarwal¹⁶, Vikas Agarwal¹⁷ and Latika Gupta¹⁸, ¹Taichung Veterans General Hospital, Taichung, Taiwan, ²Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung City, Taiwan, ³Centro de Estudios de Reumatología y Dermatología SAS, Cali, Colombia, ⁴King's College London, London, United Kingdom, ⁵University of Leeds, Leeds, United Kingdom, ⁶Southport & Ormskirk NHS Foundation Trust, Liverpool, United Kingdom, ⁷Seth Gordhandhas Sunderdas Medical College and King Edwards Memorial Hospital, Mumbai, India, ⁸Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ⁹Walter and Eliza Hall Institute, Melbourne, Australia, ¹⁰Mymensingh Medical College, Faridpur, Bangladesh, ¹¹Medical Faculty, Sofia University St. Kliment Ohridski, Sofia, Bulgaria, ¹²Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK; Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Salford, UK. Orcid ID: 0000-0002-9230-4137., Manchester, United Kingdom, ¹³REUMACARIBE IPS, Barranquilla, Colombia, ¹⁴Maulana Azad Medical College, 2-Bahadurshah Zafar Marg, New Delhi, Delhi-110002, India., Dalhi, India, ¹⁵The University of Manchester, Sale, United Kingdom, ¹⁶University of Pittsburgh, Pittsburgh, PA, ¹⁷Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ¹⁸Royal Wolverhampton Trust, Wolverhampton/University of Manchester, United Kingdom
Background/Purpose: Existing studies have shown that disease activity of patients with rheumatoid arthritis (RA) may surge after COVID-19 infection. However, factors associated with disease flares…
Abstract Number: 0387 • ACR Convergence 2023
The Association Between Inflammation, High-Sensitivity Cardiac Troponin T, and Cardiovascular Events in Rheumatoid Arthritis
Brittany Weber¹, Dana Weisenfeld¹, Mary Jeffway¹, Jonathan Coblyn¹, Michael Weinblatt², Nancy Shadick³, Marcelo DiCarli¹ and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Harvard Medical School, Waban, MA, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Patients with rheumatoid arthritis (RA) have a 1.5x excess risk of cardiovascular (CV) disease compared to the general population, attributed to chronic inflammation. In…
Abstract Number: 0403 • ACR Convergence 2023
Disease Activity Is Associated with Frailty in Veterans with Rheumatoid Arthritis
Courtney Loecker¹, Bryant England², Punyasha Roul², Namrata Singh³, Kaleb Michaud², Lani Zimmerman⁴, Myra Schmaderer⁴, Grant Cannon⁵, Ted R Mikuls⁶, Gary Kunkel⁷, Ariela Orkaby⁸, Joshua Baker⁹ and K Wysham¹⁰, ¹University of Nebraska Medical Center;VA Nebraska-Western Iowa Health Care System, Lincoln, NE, ²University of Nebraska Medical Center, Omaha, NE, ³University of Washington, Bellevue, WA, ⁴University of Nebraska Medical Center, Lincoln, NE, ⁵University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁶Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁷VA Salt Lake City & University of Utah, Salt Lake City, UT, ⁸Veterans Affairs Boston Healthcare System & Brigham and Women’s Hospital, Harvard Medical School, Boston, MA; VA Geriatric Research Education and Clinical Center, Boston, MA, ⁹University of Pennsylvania, Philadelphia, PA, ¹⁰VA Puget Sound/University of Washington, Seattle, WA
Background/Purpose: Frailty, defined as an increased vulnerability to stressors and adverse health outcomes, is an emerging concept in RA. Active RA disease gives rise to…
Abstract Number: 0420 • ACR Convergence 2023
Associations and Mortality Impact of Machine Learning-derived Quantitative Computed Tomography Parenchymal Lung Features in Rheumatoid Arthritis and non-RA Comparators in a Multicenter Prospective Cohort of Smokers
Gregory McDermott¹, Keigo Hayashi¹, Matthew Moll¹, Michael Cho¹, Kazuki Yoshida¹, Tracy J. Doyle¹, Gregory Kinney², Paul Dellaripa³, Zachary Wallace⁴, Elizabeth Regan⁵, Gary Hunninghake¹, Edwin Silverman¹, Samuel Ash¹, Raul San Jose Estepar¹, George Washko¹ and Jeffrey Sparks⁶, ¹Brigham and Women's Hospital, Boston, MA, ²University of Colorado Denver, Denver, CO, ³Brigham and Women's Hospital, Boston, MA, ⁴Massachusetts General Hospital, Newton, MA, ⁵National Jewish Health, Denver, CO, ⁶Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Quantitative computed tomography (QCT) methods have been developed to automatically quantify parenchymal lung features on chest CT imaging. There have been limited investigations of…
Abstract Number: 0437 • ACR Convergence 2023
Comparative Safety of Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for Cardiovascular Outcomes in Rheumatoid Arthritis
Xavier Sendaydiego¹, Laura Gold², K Wysham³, Jean liew⁴, Maureen Dubreuil⁵, James Andrews¹, Pankti Reid⁶, David Liew⁷, Radjiv Goulabchand⁸, Abha Singh⁹, Grant Hughes¹, Mathilde Pioro¹, Jeffrey Sparks¹⁰, Jeffrey Jarvik², Siddharth Singh⁹ and Namrata Singh¹¹, ¹University of Washington, Seattle, WA, ²Department of Radiology and University of Washington Clinical Learning, Evidence, and Research (CLEAR) Center for Musculoskeletal Disorders, Seattle, WA, ³VA Puget Sound/University of Washington, Seattle, WA, ⁴Boston University, Boston, MA, ⁵Department of Rheumatology, Boston University School of Medicine, Milton, MA, ⁶University of Chicago Medical Center, Chicago, IL, ⁷Austin Health, Heidelberg, Australia, ⁸St. Eloi Hospital, Department of Internal Medicine and Multi-Organic Diseases, Montpellier, France, ⁹University of California San Diego, San Diego, CA, ¹⁰Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ¹¹University of Washington, Bellevue, WA
Background/Purpose: Concern has arisen over the safety of Janus kinase inhibitors (JAKi) regarding cardiovascular (CV) outcomes in patients with rheumatoid arthritis (RA) with CV risk…
Abstract Number: 0454 • ACR Convergence 2023
Rheumatoid Arthritis Disease Activity Indices Assess More Than Inflammation: 29%-36% of Patients with Moderate or High DAS28–ESR or CDAI Have 0 or 1 Swollen Joints, but Positive Screens on MDHAQ FAST4 (fibromyalgia Assessment Screening Tool) And/or MDS2 (MDHAQ Depression Screen) Indices
Theodore Pincus¹, Nicholas Rodwell² and Rahel Hunter¹, ¹Rush University Medical Center, Chicago, IL, ²University of New South Wales, Sydney, Australia
Background/Purpose: Rheumatoid arthritis (RA) therapy is recommended to be intensified according to treat-to-target if DAS28 (disease activity score 28) or CDAI (clinical disease activity index)…
Abstract Number: 0732 • ACR Convergence 2023
Should Complete B-cell Depletion Be Maintained in Patients Treated Long-term with Rituximab for Rheumatoid Arthritis?
Roba Ghossan¹, Omar AL TABAA², Alice Combier³, Alexia STEELANDT³, Marion THOMAS³, Olivier Fogel³, Corinne MICELI⁴, Anna Molto³ and Jérôme Avouac⁵, ¹COCHIN HOSPITAL, Paris, France, ²APHP / Cochin Hospital, Paris, France, ³HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ⁴Université de Paris Cité, HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ⁵Service de Rhumatologie, Hôpital Cochin, AP-HP.Centre – Université Paris Cité, Paris, France
Background/Purpose: Complete peripheral B cell depletion has been considered as a relevant indicator of short-term response to rituximab (RTX) in rheumatoid arthritis (RA). The purpose…
Abstract Number: 0796 • ACR Convergence 2023
Role of Group 2 Innate Lymphoid Cells in the Pathogenesis of Rheumatoid Arthritis
Anders Nguyen¹, Agnieszka Lastowska¹, Miriam Bollmann¹, Symeon Kourmoulakis¹, Charlotte E. van der Plas¹, Anna-Karin Hultgård Ekwall², Dietmar M. Zaiss³, Gary S Firestein⁴ and Mattias N.D Svensson⁵, ¹Department of Rheumatology and Inflammation research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ²Department of Rheumatology and Inflammation research, Sahlgrenska Academy, University of Gothenburg, Kullavik, Sweden, ³Faculty of Medicine, Department of Immune Medicine, University of Regensburg, Regensburg, Germany, Regensburg, Germany, ⁴Department of Medicine, University of California San Diego, La Jolla, CA, ⁵University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Immune-cell mediated activation of joint-lining fibroblast-like synoviocytes (FLS) play a key role in joint inflammation and destruction during Rheumatoid arthritis (RA). Thus, identifying factors…
Abstract Number: 0860 • ACR Convergence 2023
Vagus Nerve Stimulation Enhances Bone Morphology in a Rodent Model of Central Nervous System Inflammation
Chandramohan Natarajan¹, Julia Lucchino¹, David Chenoff² and Yaakov Levine¹, ¹SetPoint Medical, Valencia, CA, ²SetPoint Medical, Sausalito, CA
Background/Purpose: Electrical stimulation of the vagus nerve activates the inflammatory reflex to inhibit cytokines and decrease clinical signs and symptoms of chronic inflammatory disease such…
Abstract Number: 0991 • ACR Convergence 2023
Trends in Arthroplasty Utilization for Inflammatory Arthritis Including Rheumatoid Arthritis and Spondyloarthritis in China: Analysis of a Large National Database
Dongxing Xie¹, Qiao Jiang², Yuqing Wang², Huizhong Long², Hu Chen³, Jie Wei⁴, Xiaoxiao Li⁵, Haibo Wang⁶, Chao Zeng⁷ and Guanghua Lei⁷, ¹Xiangya Hospital, Central South University, Changsha, China, ²Xiangya Hospital, Changsha, China, ³Tibet Autonomous Region People’s Hospital, Lhasa, China, ⁴Health Management Center, Xiangya Hospital Central South University, Changsha, China, ⁵Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University, Changsha, China, ⁶China Standard Medical Information Research Center, Shenzhen, China, ⁷Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China
Background/Purpose: For end-stage inflammatory arthritis (IA) including rheumatoid arthritis (RA) and spondyloarthritis (SpA), joint arthroplasty is the only treatment option, but is considered to be…
Abstract Number: 1067 • ACR Convergence 2023
A Comparison of Joint Involvement Patterns in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis and Rheumatoid Arthritis
Carlos Aude¹, Deanna Jannat-Khah², Karmela Kim Chan², Nilasha Ghosh¹, Clifton Bingham³, Vivian Bykerk² and Anne Bass¹, ¹Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ²Hospital For Special Surgery, New York, NY, ³Johns Hopkins University, Baltimore, MD
Background/Purpose: Immune checkpoint inhibitors (ICIs) have transformed cancer treatment but may trigger immune-related adverse events (irAEs) such as ICI-induced inflammatory arthritis (ICI-IA). Although ICI-IA and…
Abstract Number: 1271 • ACR Convergence 2023
Upregulation of IFNγ-Response Genes in Monocytes and T Cells Identified by Single-Cell Transcriptomics in Patients with Anti-CCP Antibody-Positive Rheumatoid Arthritis (RA)
Bong-Ki Hong¹, Sungyong You², Naeun Lee¹, Jung Gon Kim³, Kijun Lee⁴, Ji Hyeon Ju⁵, Wan-Uk Kim¹ and Ho-Youn Kim⁶, ¹The Catholic University of Korea, Seoul, South Korea, ²Cedars-Sinai Medical Center, Los Angeles, CA, ³Inje University Ilsan Paik Hospital, Goyang, South Korea, ⁴YiPSCELL, Secho, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁶HoYoun Kim's Clinic for Arthritis Rheumatism, Seoul, South Korea
Background/Purpose: Recent research has revealed a significant upregulation of IFNγ-related genes in RA patients, though the underlying mechanisms and implications are still unclear. To further…
Abstract Number: 1287 • ACR Convergence 2023
Impact of Body Mass Index (BMI) on Rheumatoid Arthritis Disease Activity and Musculoskeletal Ultrasound Measures
Nicolette Morris¹, Elena Saab², Lucia Chen¹, Jenny Brook¹, Gurjit S Kaeley³, David Elashoff¹ and Veena Ranganath¹, ¹David Geffen School of Medicine, UCLA, Los Angeles, CA, ²Wake Forest University School of Medicine, Los Angeles, CA, ³University of Florida College of Medicine – Jacksonville, Ponte Vedra Beach, FL
Background/Purpose: Rheumatoid arthritis (RA) patients with obesity are less likely to respond to therapy and achieve remission. Obesity is a known driver of inflammatory processes…
Abstract Number: 1303 • ACR Convergence 2023
Patient’s and Physician’s Evaluation of Global Assessment of Disease Activity over Follow up and Across Disease Activity Levels in Recent-Onset Rheumatoid Arthritis
Audrey-Anne Couture¹, Nathalie Carrier², Hugues Allard-Chamard³, Sophie ROUX³, Patrick Liang³ and Gilles Boire³, ¹University of Montréal, Montréal, QC, Canada, ²CIUSSS de l'Estrie - CHUS, Sherbrooke, QC, Canada, ³Université de Sherbrooke, Sherbrooke, QC, Canada
Background/Purpose: Composite measures (e.g. SDAI) to assess Rheumatoid Arthritis (RA) disease activity incorporate patient (PGA) and evaluator (EGA) global assessments. EGA and PGA are often…
Abstract Number: 1319 • ACR Convergence 2023
Real World Data on Antifibrotics in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 73 Patients
Belén Atienza-Mateo¹, Ana Serrano-Combarro², Maria Martin-Lopez³, Santos Castañeda⁴, Rafael Benito Melero-Gonzalez⁵, Jesus Loarce-Martos⁶, Natalia Mena Vazquez⁷, Carmen carrasco-Cubero⁸, Carolina Diez-Morrondo⁹, David Castro-Corredor¹⁰, Tomás Vazquez-Rodriguez¹¹, andrea Garcia-Valle¹², Gema Bonilla¹³, Marina Rodriguez-lopez¹⁴, Ignacio Brana Abascal¹⁵, SARA MARIA ROJAS HERRERA¹⁶, Juan Camilo Sarmiento-Monroy¹⁷, Pablo Andujar-Brazal¹⁸, Juan Ramon De Dios¹⁹, Carmen Gonzalez-Montagut Gomez²⁰, Sergio Ordonez-Palau²¹, Anahy Maria Brandy-Garcia²², Fernando Lozano²³, Maria Lopez-Lasanta²⁴, Cristina Campos Fernández²⁵, Marta Garijo Bufort²⁶, Ivette Casafont-Sole²⁷, Calderon Goercke²⁸, Carlota Laura Iñiguez²⁹, Francisco Ortiz-Sanjuán³⁰, Emilio Giner-Serret³¹, Bryan Josue Flores Robles³², Mireia Moreno³³, Evelin Cecilia Cervantes-Perez³⁴, Diego Ferrer³⁵, Ricardo Blanco³⁶ and On behalf of the Collaborative Group Members³⁷, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain, ³Hospital 12 de Octubre, Madrid, Spain, ⁴Hospital Universitario de la Princesa, Madrid, Spain, ⁵CHU Vigo, O Carballino, Spain, ⁶Ramón y Cajal University Hospital, Madrid, Spain, ⁷IBIMA, Málaga, Spain, ⁸Department of Rheumatology, Hospital Universitario de Badajoz, Badajoz, Spain, ⁹Division of Rheumatology, Hospital de León, León, Spain, ¹⁰General University Hospital of Ciudad Real, Santa Cruz de Mudela (Ciudad Real), Spain, ¹¹Rheumatology, Complejo Hospitalario Universitario de Ferrol, A Coruña, Spain, ¹²Division of Rheumatology, Complejo Asistencial Universitario de Palencia, Palencia, Spain, ¹³Department of Rheumatology, Hospital Clínico Universitario La Paz, Madrid, Spain, ¹⁴Division of Rheumatology, Hospital Clínico Universitario de Santiago, La Coruna, Spain, ¹⁵Division of Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Spain, ¹⁶Division of Rheumatology, Hospital de Mérida, Mérida, Spain, ¹⁷Hospital Clínic, Barcelona, Spain, ¹⁸Division of Rheumatology, Hospital Universitario Doctor Peset, Valencia, Spain, ¹⁹Hospital Universitario Araba, Vitoria, Spain, ²⁰H. Clínico Universitario de Valladolid, Valladolid, Spain, ²¹H. Arnau de Vilanova, Lleida, Spain, ²²Hospital Germans Trias i Pujol, Badalona, Spain, ²³Hospital Universitario 12 de Octubre, Madrid, Spain, ²⁴Hospital Universitari Vall d'Hebron, Rheumatology, Barcelona, Spain, ²⁵Hospital General Universitario Valencia, Valencia, Spain, ²⁶H. de Sagunto, Valencia, Italy, ²⁷Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²⁸Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²⁹Hospital Universitario Lucus Augusti, Lugo, Spain, ³⁰Hospital Universitario y Politécnico La Fe, Valencia, Spain, ³¹Hospital Royo Villanova, Teruel, Spain, ³²Hospital Universitario San Pedro, Logroño, Spain, ³³Parc Tauli Hospital Universitari, I3PT(UAB), Barcelona, Spain, ³⁴Complexo Hospitalario Universitario de Pontevedra, Pontevedra, Spain, ³⁵Division of Pneumology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³⁶Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³⁷Spanish Collaborative Group of Interstitial Lung Disease Associated with Rheumatoid Arthritis, Spain, Spain
Background/Purpose: Interstitial lung disease (ILD) is a critical complication of rheumatoid arthritis (RA). Abatacept and rituximab are the preferred disease-modifying antirheumatic drugs (DMARDs) for RA-ILD.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.